BusinessKura Oncology to Report Third Quarter 2017 Financial ResultsBy Nasdaq OMXOct 31, 2017, 8:05 PM UTC
BusinessKura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AMLBy Nasdaq OMXOct 28, 2017, 4:30 PM UTC
BusinessKura Oncology Lead Candidate Tipifarnib Shows Durable Anti-Tumor Activity in HRAS Mutant Head and Neck Cancer in AACR-NCI-EORTC UpdateBy Nasdaq OMXOct 27, 2017, 2:50 PM UTC
BusinessKura Oncology Announces Late-Breaking Presentations for Tipifarnib in HRAS Mutant Squamous Head and Neck Cancer and for KO-539 in AML at Upcoming AACR-NCI-EORTC International ConferenceBy Nasdaq OMXOct 16, 2017, 11:30 AM UTC
BusinessKura Oncology Announces Pricing of Public Offering of Common StockBy Nasdaq OMXAug 11, 2017, 2:12 AM UTC
BusinessKura Oncology Announces Commencement of Public Offering of Common StockBy Nasdaq OMXAug 9, 2017, 8:17 PM UTC
BusinessKura Oncology to Report Second Quarter 2017 Financial ResultsBy Nasdaq OMXJul 31, 2017, 11:30 AM UTC
BusinessKura Oncology Presents Preclinical Data on KO-947 and Menin-MLL Inhibitor Program at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsBy Nasdaq OMXDec 1, 2016, 12:30 PM UTC
